Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study
Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study Prostate Cancer and Prostatic Diseases advance online publication, September 24 2013. doi:10.1038/pcan.2013.34 Authors: A Lustman, S Nakar, A D Cohen &S Vinker
The study couldn't prove cause and effect, but it found that statins, taken alone or with metformin, did seem associated with an increase in survival.
FRIDAY, Feb. 14, 2020 -- Drugs that many men with prostate cancer might already be taking -- cholesterol-lowering statins -- may help extend their survival if they have a " high-risk " form of the disease, new research suggests. High-risk patients...
ConclusionsStatin use alone or in combination with metformin was associated with lower all ‐cause and PCa mortality among high‐risk patients, particularly in post‐diagnostic settings; further studies are warranted.
(Thomas Jefferson University) Statin use alone or with metformin is associated with lower prostate cancer mortality from all causes, among high-risk patients.
Prostate Cancer and Prostatic Diseases, Published online: 06 February 2020; doi:10.1038/s41391-020-0207-5Associations among statins, preventive care, and prostate cancer mortality
Telephone intervention linked to rise in men ’s vegetable consumption but not to drop in risk of progression Related items fromOnMedica Less regular PSA screening puts men at risk NICE guidance delays hinder good diabetes care Population weight control best for cutting diabetes prevalence Starting statins not beneficial in many older adults NHS must hold CCGs accountable for poor diabetes care
ConclusionMetformin and statins were not associated with BFFS or DFFS improvement in our analysis. However, the small number of patients treated with these drugs limits the reliability of the results and prospective studies are needed.
MONDAY, Dec. 2, 2019 -- Current statin use is inversely associated with the risk for lethal prostate cancer, according to a study published online Nov. 21 in Clinical Cancer Research. Emma H. Allott, Ph.D., from Queen's University Belfast in the...
Researchers at Queen's University in Belfast suggested the cholesterol-lowering drugs could reduce swelling the prostate and avoid deadly cancer, but overall rates of cancer were unchanged.
CONCLUSIONS: Molecular tumor classification identified PTEN and inflammation/immune activation as potential mechanisms linking statins with lower lethal prostate cancer risk. These findings support a potential causal association and could inform selection of relevant biomarkers for statin clinical trials. PMID: 31754047 [PubMed - as supplied by publisher]